Unaudited Financial Results for the quarter and nine months ended December 31, 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 8.9 pts less than Nifty Microcap 250 and 8.8 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
The board approved unaudited standalone results for Q3 FY26 (quarter ended Dec 31, 2025) and the nine-month period. Revenue from operations was nil in Q3 FY26, the same as in Q3 FY25, though the company had reported ₹52.57 lakh in Q2 FY26. Total revenue for the nine months stood at ₹54.64 lakh versus ₹78.39 lakh a year earlier. The company swung to a loss of ₹8.65 lakh in Q3 FY26, against a profit of ₹9.80 lakh in Q2 FY26. For the nine months, it posted a steep loss of ₹11.79 crore, compared to a profit of ₹68.18 lakh in the same period last year, translating to a loss per share of ₹78.62. The blow-out loss was driven by administrative and other expenses ballooning to ₹11.90 crore in 9M FY26 from just ₹8.03 lakh a year ago. Auditor SSRV & Associates issued a clean limited review report.
The sharp, unexplained surge in administrative expenses has wiped out profitability and produced a near ₹12 crore nine-month loss, which is likely to weigh negatively on the stock and raise serious questions for shareholders about the nature of these costs and the company's financial health going forward.